Navigation Links
First CyberKnife in Saudi Arabia to be Installed at Prestigious King Faisal Specialist Hospital and Research Center
Date:10/8/2008

SUNNYVALE, Calif., Oct. 8 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that the first CyberKnife(R) Robotic Radiosurgery System in the Kingdom of Saudi Arabia will be installed at the prestigious King Faisal Specialist Hospital and Research Center in Riyadh. It is the first CyberKnife System to be installed in the Middle East region.

King Faisal Specialist Hospital, the leading medical institution in Saudi Arabia, has the largest cancer treatment facility in the Gulf region and was established to become the premier international center for cancer research in prevention and treatment.

Accuray's CyberKnife System is the first and only robotic radiosurgery system to enable non-invasive treatment of tumors anywhere in the body with sub-millimeter precision. The CyberKnife System tracks and detects -- in real-time -- movement of the patient and tumor during treatment and can automatically adjust the position of the radiation beam to minimize damage to healthy surrounding tissue.

"Because of its accuracy and non-invasive nature, the CyberKnife System can offer an alternative to patients who may not be able to tolerate other cancer treatments or who have medically inoperable tumors," said Mohammad Al Shabanah, M.D., head of Radiation Oncology at King Faisal Specialist Hospital. "CyberKnife radiosurgery delivers precise beams of radiation from many angles outside the body without requiring the use of a metal head frame used in previous treatments, which will eliminate the pain and inconvenience for patients."

"With a full range of cancer treatments, King Faisal Specialist Hospital is delivering on its promise to offer comprehensive, state-of-the-art care to patients across Saudi Arabia," said Belal Moftah, Ph.D., chairman of the Department of Biomedical Physics at King Faisal Specialist Hospital. "Our management is determined to make King Faisal Specialist Hospital the leading institution in the region in all ranges of radiotherapy services."

"We are happy that a leading tertiary hospital such as King Faisal Specialist Hospital will be able to provide state-of-the-art cancer care with the CyberKnife System," said Eric P. Lindquist, senior vice president and chief marketing officer of Accuray Incorporated. "With the addition of the CyberKnife System, the Cancer Center can further expand its capabilities and offer treatments for patients who may not have had other options until now."

About King Faisal Specialist Hospital & Research Centre

KFSH&RC is an 894-bed multi-facility, multi-entity tertiary care hospital and one of the leading healthcare institutions in the Kingdom of Saudi Arabia. Its mission is to provide medical services of highly specialized nature and promote medical research and education programs, including postgraduate education training, as well as contribute to the prevention of disease.

About King Faisal Cancer Centre

The King Faisal Cancer Centre (KFCC) is a newly established structure for cancer care of adult patients with a mission of providing excellent cancer treatment, education and research by means of integrated team work and the vision to become the best international centre for cancer research, prevention, and treatment. Accredited by the World Health Organization (WHO) as a Collaborating Center for Cancer Prevention and Control, KFCC patients are assessed in multidisciplinary clinics and treated in accordance with disease specific internationally accepted management guidelines. KFCC houses the National Cancer Registry and the Gulf Council Countries (GCC) Cancer Registry which defines population-based incidence of cancer in the Kingdom.

About the CyberKnife(R) Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 50,000 patients worldwide and currently more than 140 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit http://www.accuray.com.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to clinical studies, regulatory review and approval, and commercialization of products are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the year ended June 30, 2008 as updated from time to time by our quarterly reports on Form 10-Q and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.


'/>"/>
SOURCE Accuray Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Solos Endoscopy, Inc. Posts First Six Months Financials of 2008 on Pinksheets.com
2. Medifast Announces Opening of First Franchise Clinic
3. Archus Orthopedics Performs First Facet Replacement Procedure With an Artificial Disc
4. Candice Lane MD Launches Hormone Health MD Plus: The First Doctor Bioidentical Hormone Blog
5. Dr. Gail Golab, Head of AVMA Animal Welfare Division, Becomes First U.S. Veterinarian Credentialed in Animal Welfare
6. Argentyn 23(R) Homeopathic First Aid Gel - Another Worlds First by Natural-Immunogenics Corp. for Healthcare Professionals
7. Researchers create first model for retina receptors
8. Scripps Research Institute and IAVI launch worlds first dedicated HIV neutralizing antibody center
9. First Dedicated Cancer Hospital Coming to North Texas
10. Statewide Gambling Conference -- Series of Firsts -- Begins 9-30-08
11. Modular Building Systems International (MBSI) Supplies Buildings For First Platinum Certified Green Modular School In The U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... ... (ONS) wanted to create a communications platform that positions them as the go-to ... and ONS reinvented their online publication as an always-on, always-fresh news, views and ...
(Date:3/24/2017)... ... March 24, 2017 , ... The law firm of ... is pleased to announce Westchester resident Lauren C. Enea has joined the firm as ... firm, will concentrate her practice in elder law, Medicaid planning and applications, and Wills, ...
(Date:3/24/2017)... ... March 24, 2017 , ... Empower Brokerage, ... their training and leads programs. , In February, 2017, Empower Brokerage introduced their ... Performance Partners is designed to teach how to maximize their sales efforts, as ...
(Date:3/24/2017)... ... 2017 , ... “End Time GPS”: a dauntless and enlightened study of ... GPS” is the creation of published author, Wesley Gerboth, a World War II veteran, ... space-vehicle projects. Now, at age ninety-one, he shares the Wisdom God bestowed upon him ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Adventures of Joey, The Dog ... dog who lives his life to the fullest, as God intended. “The Adventures of ... Holmgren, a mother and grandmother pursuing her passion for writing, especially about truth and ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)...   The Accreditation Council for Medical Affairs ... the pharmaceutical industry has appointed Dr. Jane ... formed scientific advisory board. Dr. Chin will be ... ever medical affairs think tank within the pharmaceutical ... ACMA, please visit  www.medicalaffairsspecialist.org .  Connect with ...
(Date:3/24/2017)... FinancialBuzz.com News Commentary  ... According to new data published Arcview ... legal cannabis market is projected to continue to grow at ... the current presidential administration. The report created by Arcview,s data ... growth in this industry are the passage and subsequent implementation ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of the ... their offering. ... pipeline is very strong with a total of 97 drug candidates. Pharma ... Sanofi are involved in the development of the IPF therapeutics. The IPF ... III stage, 15 are in Phase II stage, 12 are in Phase ...
Breaking Medicine Technology: